Archit Organosys Ltd

As of November 13, 2025, Archit Organosys is considered overvalued with a PE ratio of 147.70, significantly higher than its peers, and has underperformed the Sensex with a year-to-date return of -6.00%.

Archit Organosys has experienced a declining trend in net sales and profits, with net sales dropping from 137.90 Cr in March 2022 to 113.19 Cr in March 2024, and profit after tax decreasing from 11.35 Cr to 3.28 Cr in the same period. Key financial metrics indicate a challenging performance, highlighted by a significant reduction in operating profit margin and earnings per share.

As of 11-Nov, Archit Organosys Ltd's stock price is at 45.48, showing a slight increase after two days of decline, but it has underperformed against the Sensex over the past week, month, and year. Despite trading above some moving averages, the stock's overall performance remains negative, indicating challenges in the current market context.

The next results date for Archit Organosys is 13 November 2025.

Archit Organosys has experienced a consistent decline in net sales and profits from March 2022 to March 2024, with net sales dropping from 137.90 Cr to 113.19 Cr and profit after tax decreasing from 11.35 Cr to 3.28 Cr. The operating profit margin also fell significantly, indicating challenging financial performance.

As of October 30, 2025, Archit Organosys is considered overvalued with a high PE ratio of 150.72 and poor alignment with earnings growth potential, despite being rated attractive compared to peers like Godrej Industries and Solar Industries.

As of October 29, 2025, Archit Organosys is fairly valued with a PE ratio of 153.25 and an EV to EBITDA of 18.74, despite recent underperformance compared to the Sensex, but it has shown strong long-term growth with a 5-year return of 175.21%.

Archit Organosys has experienced a decline in net sales and profits, with net sales dropping from 137.90 Cr in March 2022 to 113.19 Cr in March 2024, and profit after tax decreasing from 11.35 Cr to 3.28 Cr in the same period. The earnings per share also fell from 5.53 to 1.6, indicating a challenging financial environment.

Archit Organosys has experienced a decline in net sales and profits from March 2022 to March 2024, with net sales dropping from 137.90 Cr to 113.19 Cr and profit after tax decreasing from 11.35 Cr to 3.28 Cr during this period. Overall, the company's financial metrics indicate a challenging trend with reduced revenues and earnings.

As of October 17, 2025, Archit Organosys is considered overvalued with a high PE ratio of 154.30 and an EV to EBIT of 107.77, despite its attractive valuation grade, as it has underperformed compared to peers and the Sensex over the past three years.

As of October 17, 2025, Archit Organosys is considered undervalued with an attractive valuation grade, highlighted by a PE ratio of 154.30 and strong growth potential, despite recent stock performance lagging behind the Sensex.

As of October 17, 2025, Archit Organosys is considered undervalued with an attractive valuation grade, highlighted by a low PEG ratio of 0.02 and a high PE ratio of 154.30, indicating strong growth potential despite recent stock performance lagging behind the Sensex.

Archit Organosys has shown a declining trend in financial performance, with net sales dropping from 137.90 Cr in March 2022 to 113.19 Cr in March 2024, and profit after tax decreasing from 11.35 Cr to 3.28 Cr over the same period. Key metrics such as operating profit and earnings per share have also significantly declined.

As of October 15, 2025, Archit Organosys is fairly valued with a PE ratio of 152.53 and an EV to EBITDA of 18.67, despite underperforming the Sensex, while its peers show varying valuations, with Solar Industries being very expensive and Godrej Industries attractive.

As of October 9, 2025, Archit Organosys is considered undervalued with an attractive valuation grade, highlighted by a high PE ratio of 97.23, a favorable PEG ratio of 0.01, and a 3.00% return over the past year, outperforming the Sensex's 0.87%.

As of October 8, 2025, Archit Organosys is considered overvalued with a valuation grade of fair due to a high PE ratio of 94.81 and poor long-term performance, despite a recent stock return of 1.87% that outperformed the Sensex.

As of 24-Sep, Archit Organosys Ltd's stock price is Rs 47.15, down 3.1% and has declined 4.86% over the last three days. The stock is underperforming compared to the Sensex, with a year-to-date drop of 1.36% and a significant decrease in trading volume, indicating a lack of investor confidence.

As of September 23, 2025, Archit Organosys is considered overvalued with a high PE ratio of 98.91 and poor capital efficiency reflected in a ROCE of 1.27%, making it less attractive compared to peers like Godrej Industries, despite a strong 5-year return of 261.59%.